Published Technical Disclosure Archive

Enhanced Compositions and Methods for Treating Spinal Muscular Atrophy

Publication ID: 24-11857599_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Compositions and Methods for Treating Spinal Muscular Atrophy,” Published Technical Disclosure No. 24-11857599_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857599_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,599.

Summary of the Inventive Concept

This inventive concept discloses improved compositions and methods for treating spinal muscular atrophy (SMA), addressing the limitations of existing treatments by enhancing efficacy, reducing off-target effects, and improving delivery to the central nervous system.

Background and Problem Solved

The original patent disclosed a method of treating SMA using recombinant ALK4:ActRIIB heteromultimers. However, these treatments have limitations, including suboptimal delivery, off-target effects, and variable efficacy. The new inventive concept addresses these limitations by introducing controlled-release delivery devices, co-administration with TGF-β superfamily ligand antagonists, and optimized compositions for enhanced bioavailability in the central nervous system.

Detailed Description of the Inventive Concept

The new inventive concept comprises four key aspects: 1) a system for treating SMA featuring a recombinant ALK4:ActRIIB heteromultimer and a controlled-release delivery device, ensuring sustained therapeutic effects; 2) a method for enhancing efficacy by co-administering the heteromultimer with a TGF-β superfamily ligand antagonist, reducing off-target effects; 3) a composition featuring the heteromultimer and a pharmaceutically acceptable carrier optimized for central nervous system bioavailability; and 4) a method for monitoring efficacy by measuring SMN protein levels in motor neurons before and after treatment.

Novelty and Inventive Step

The new inventive concept introduces novel combinations of components and methods that improve upon the original patent. Specifically, the controlled-release delivery device, co-administration with TGF-β superfamily ligand antagonists, and optimized compositions for central nervous system bioavailability are non-obvious improvements over the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include different delivery device designs, alternative TGF-β superfamily ligand antagonists, and modified compositions for targeting specific SMA subtypes. Variations could also include combination therapies with other SMA treatments or administration routes.

Potential Commercial Applications and Market

The enhanced compositions and methods for treating SMA have significant commercial potential in the orphan drug market, offering improved treatment options for patients with this debilitating disease. The market potential is substantial, with an estimated global SMA market size projected to reach $1.5 billion by 2025.

CPC Classifications

SectionClassGroup
A A61 A61K38/1841
A A61 A61K31/7125
A A61 A61K38/18
A A61 A61K45/06
A A61 A61P21/00
C C07 C07K14/71
C C12 C12N15/113
A A61 A61K38/179
C C07 C07K2319/30
C C07 C07K2319/32
C C12 C12N2310/11
C C12 C12N2320/31

Field of Art

Biotechnology and pharmaceutical research, specifically neuromuscular disorder therapeutics, with expertise in protein engineering, drug delivery systems, and genetic disease treatment strategies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, experienced in protein modification, drug formulation, and understanding of neuromuscular disease mechanisms, familiar with protein fusion technologies and targeted therapeutic approaches

Obviousness Rationale

A person having ordinary skill would recognize that the PTD represents predictable variations on the source patent's core ALK4:ActRIIB heteromultimer technology. The disclosed improvements in delivery mechanism, co-administration strategies, and bioavailability optimization represent logical extensions of the original therapeutic approach. These variations demonstrate standard problem-solving techniques in biotechnology drug development, applying known techniques to enhance existing treatment modalities.

Obvious Combinations & Variations

Source Patent Element
ALK4:ActRIIB heteromultimer for treating spinal muscular atrophy
PTD Variation
Adding a controlled-release delivery device to modulate heteromultimer administration
Obviousness Reasoning
Controlled drug delivery is a well-established technique in pharmaceutical engineering, representing a predictable optimization of existing therapeutic approaches
Source Patent Element
Method of treating SMA using protein fusion technology
PTD Variation
Co-administering with TGF-β superfamily ligand antagonist to reduce off-target effects
Obviousness Reasoning
Combination therapies and pharmacological optimization are standard approaches in managing complex genetic disorders, representing an obvious refinement of existing treatment strategies
Source Patent Element
Treatment method targeting motor neuron protein levels
PTD Variation
Introducing quantitative monitoring of SMN protein levels as treatment efficacy metric
Obviousness Reasoning
Developing precise diagnostic and monitoring techniques is a routine practice in translational medical research, representing an expected progression of therapeutic methodology
Source Patent Element
SMA treatment using protein fusion technology
PTD Variation
Optimizing pharmaceutical carrier for enhanced central nervous system bioavailability
Obviousness Reasoning
Improving drug delivery mechanisms through carrier modification is a standard approach in pharmaceutical development, representing a predictable technical solution
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857599, the present publication demonstrates that the claimed variations in SMA treatment methodology would have been obvious to a person having ordinary skill in the art at the time of invention. The disclosed improvements represent predictable extensions of existing protein fusion and therapeutic delivery technologies, utilizing standard biotechnological problem-solving approaches to enhance treatment efficacy and reduce potential side effects.

Original Patent Information

Patent NumberUS 11,857,599
TitleCompositions and methods for treating spinal muscular atrophy
Assignee(s)ACCELERON PHARMA INC.